Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3-Reference-Cited by-同舟云学术

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Published:2024-08 Issue:8 Volume:35 Page:718-727
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Goetz M.P.,Toi M.,Huober J.,Sohn J.,Trédan O.,Park I.H.,Campone M.,Chen S.-C.,Manso L.M.,Paluch-Shimon S.,Freedman O.C.,O’Shaughnessy J.,Pivot X.,Tolaney S.M.,Hurvitz S.A.,Llombart-Cussac A.,André V.,Saha A.,van Hal G.,Shahir A.,Iwata H.,Johnston S.R.D.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Reference25 articles.

1. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer;Johnston;NPJ Breast Cancer,2019

2. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up;Rugo;Breast Cancer Res Treat,2019

3. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2018

4. NCCN guidelines® insights: breast cancer, version 4.2023;Gradishar;J Natl Compr Canc Netw,2023

5. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer;Expert Review of Anticancer Therapy;2024-08-29

2. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

3. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study;Cancers;2024-08-17

4. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand;BMC Cancer;2024-08-16

5. Advances in Personalized Oncology;Cancers;2024-08-16